Det gennemsnitlige fald i hæmoglobinkoncentrationen fra initialværdier til undersøgelsens afslutning var 0, 9 g/ dl for de patienter, som fik bosentan og 0, 1 g/ dl for de patienter, som fik placebo.
The mean decrease in haemoglobin concentration from baseline to trial completion for the bosentan- treated patients was 0.9 g/dl and for the placebo-treated patients was 0.1 g/dl.